| Literature DB >> 12540239 |
David L Musso1, Felicia R Cochran, James L Kelley, Ed W McLean, Jeffrey L Selph, Greg C Rigdon, G Faye Orr, Ronda G Davis, Barrett R Cooper, Virgil L Styles, James B Thompson, William R Hall.
Abstract
The design of rigid cyclic analogues derived from cinnamamide 1, (E)-N-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide, and beta-methylcinnamamide 2, (E)-N-cyclopropyl-3-(3-fluorophenyl)but-2-enamide, has led to the discovery of the potent, centrally acting muscle relaxant (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 17. Compound 17 also possesses potent antiinflammatory and analgesic activity. This paper describes the synthesis and the muscle relaxant, antiinflammatory, and analgesic structure-activity relationships of 17 and 67 of its analogues. Compound 17 has been taken into phase I clinical trials.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12540239 DOI: 10.1021/jm020067s
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446